Condition
Sickle Cell Disease
Locations
Canada, France, India, Italy, Lebanon, South Africa, Spain, Turkey,
United Kingdom, United States
Start date
07/07/2022
Summary
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants get is decided by chance. Participants getting NDec and/or Placebo will get capsules to take twice weekly. The study will last for about a year.
Trial Overview:
Treatment
Drug: NDec - oral decitabine-tetrahydrouridine
Drug: HU - Hydroxyurea
Drug: Placebo
Study type
Interventional
Trial duration
Jul 07 2022 - May 29 2025
Estimated enrollment
84
Phase
II
Are you eligible?
Gender
Male and female
Age
18 years and older
Blood disorder
Other
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.